Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Nivolumab or Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT07572123Phase 3Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2026
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of nivolumab, pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by National Cancer Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT07572123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572123.